drugset / Trial / NCT03028909
Dose Ranging Study to Evaluate the Efficacy and Safety of MEDI8852 in Adults Who Are Hospitalized With Type A Influenza.
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purposes of this study are to determine if MEDI8852 administered with standard of care (oseltamivir) will reduce the time to normalization of respiratory function for adults who are hospitalized with influenza caused by Type A strains and to determine if MEDI8852 has an acceptable safety profile in adults who are hospitalized with influenza caused by Type A strains.
Timeline
- Start
- 2017-07-24
- Primary completion
- 2019-07-26
- Completion
- 2019-07-26
Outcome
Outcome not reported
Stopped: “Study is withdrawn due to company decision.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MEDI8852 | Monoclonal antibody | — | Other |
| Background | Oseltamivir | Small molecule | — | — |
Indications
No indication recorded.